首页> 外文期刊>Endocrinology and Metabolism Clinics of North America >Management of bone disease in patients undergoing hormonal therapy for breast cancer.
【24h】

Management of bone disease in patients undergoing hormonal therapy for breast cancer.

机译:激素治疗乳腺癌患者的骨病管理。

获取原文
获取原文并翻译 | 示例
           

摘要

Estrogen deficiency at menopause is associated with increased risk of bone loss and osteoporosis. Aromatase inhibitors (AIs) are increasingly being used for the treatment of postmenopausal hormone-sensitive breast cancer because of better disease-free survival compared with tamoxifen seen in clinical trials with AIs. This article reviews the effect of endocrine therapies of breast cancer on bone and the management of bone disease with these endocrine therapies. The effect of these therapies on bone mineral density and bone turnover along with possible interventions is discussed. AIs are also associated with skeletal-related events, which are not discussed.
机译:绝经期雌激素缺乏与骨质流失和骨质疏松症的风险增加有关。芳香化酶抑制剂(AIs)由于在临床试验中与他莫昔芬相比具有更好的无病生存率,因此越来越多地用于治疗绝经后激素敏感性乳腺癌。本文回顾了乳腺癌的内分泌治疗对骨的影响以及这些内分泌治疗对骨疾病的管理。讨论了这些疗法对骨矿物质密度和骨转换的影响以及可能的干预措施。 AI也与骨骼相关事件相关,因此未进行讨论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号